707 related articles for article (PubMed ID: 35200677)
21. SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution.
Zahradník J; Marciano S; Shemesh M; Zoler E; Harari D; Chiaravalli J; Meyer B; Rudich Y; Li C; Marton I; Dym O; Elad N; Lewis MG; Andersen H; Gagne M; Seder RA; Douek DC; Schreiber G
Nat Microbiol; 2021 Sep; 6(9):1188-1198. PubMed ID: 34400835
[TBL] [Abstract][Full Text] [Related]
22. Molecular insights into the binding interactions and energetics of the omicron spike variant with hACE2 and a neutralizing antibody.
Kumar V; Shefrin S; Sundar D
J Struct Biol; 2024 Jun; 216(2):108087. PubMed ID: 38494148
[TBL] [Abstract][Full Text] [Related]
23. Active components in Ephedra sinica stapf disrupt the interaction between ACE2 and SARS-CoV-2 RBD: Potent COVID-19 therapeutic agents.
Mei J; Zhou Y; Yang X; Zhang F; Liu X; Yu B
J Ethnopharmacol; 2021 Oct; 278():114303. PubMed ID: 34102269
[TBL] [Abstract][Full Text] [Related]
24. Withanone from
Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
[TBL] [Abstract][Full Text] [Related]
25. Mechanistic study of the transmission pattern of the SARS-CoV-2 omicron variant.
An K; Yang X; Luo M; Yan J; Xu P; Zhang H; Li Y; Wu S; Warshel A; Bai C
Proteins; 2024 Jun; 92(6):705-719. PubMed ID: 38183172
[TBL] [Abstract][Full Text] [Related]
26. SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein-ACE2 complex.
Mannar D; Saville JW; Zhu X; Srivastava SS; Berezuk AM; Tuttle KS; Marquez AC; Sekirov I; Subramaniam S
Science; 2022 Feb; 375(6582):760-764. PubMed ID: 35050643
[TBL] [Abstract][Full Text] [Related]
27. Molecular and computational analysis of spike protein of newly emerged omicron variant in comparison to the delta variant of SARS-CoV-2 in Iraq.
Rashid PMA; Salih GF
Mol Biol Rep; 2022 Aug; 49(8):7437-7445. PubMed ID: 35698014
[TBL] [Abstract][Full Text] [Related]
28. SARS-CoV-2 Omicron spike glycoprotein receptor binding domain exhibits super-binder ability with ACE2 but not convalescent monoclonal antibody.
Omotuyi O; Olubiyi O; Nash O; Afolabi E; Oyinloye B; Fatumo S; Femi-Oyewo M; Bogoro S
Comput Biol Med; 2022 Mar; 142():105226. PubMed ID: 35066447
[TBL] [Abstract][Full Text] [Related]
29. Discovery of Novel Spike Inhibitors against SARS-CoV-2 Infection.
Tai LT; Yeh CY; Chang YJ; Liu JF; Hsu KC; Cheng JC; Lu CH
Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892294
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
Nayak SK
Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
[TBL] [Abstract][Full Text] [Related]
31. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
[TBL] [Abstract][Full Text] [Related]
32. Scanning the RBD-ACE2 molecular interactions in Omicron variant.
Rath SL; Padhi AK; Mandal N
Biochem Biophys Res Commun; 2022 Feb; 592():18-23. PubMed ID: 35007846
[TBL] [Abstract][Full Text] [Related]
33. Assessment of mutations on RBD in the Spike protein of SARS-CoV-2 Alpha, Delta and Omicron variants.
da Costa CHS; de Freitas CAB; Alves CN; Lameira J
Sci Rep; 2022 May; 12(1):8540. PubMed ID: 35595778
[TBL] [Abstract][Full Text] [Related]
34. Corilagin prevents SARS-CoV-2 infection by targeting RBD-ACE2 binding.
Yang LJ; Chen RH; Hamdoun S; Coghi P; Ng JPL; Zhang DW; Guo X; Xia C; Law BYK; Wong VKW
Phytomedicine; 2021 Jul; 87():153591. PubMed ID: 34029937
[TBL] [Abstract][Full Text] [Related]
35. Molecular Insights into the Variability in Infection and Immune Evasion Capabilities of SARS-CoV-2 Variants: A Sequence and Structural Investigation of the RBD Domain.
Wang TH; Shao HP; Zhao BQ; Zhai HL
J Chem Inf Model; 2024 Apr; 64(8):3503-3523. PubMed ID: 38517012
[TBL] [Abstract][Full Text] [Related]
36. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A
Molecules; 2021 May; 26(11):. PubMed ID: 34072087
[TBL] [Abstract][Full Text] [Related]
37. Recognition through GRP78 is enhanced in the UK, South African, and Brazilian variants of SARS-CoV-2; An in silico perspective.
Ibrahim IM; Elfiky AA; Elgohary AM
Biochem Biophys Res Commun; 2021 Jul; 562():89-93. PubMed ID: 34049205
[TBL] [Abstract][Full Text] [Related]
38. Evolution of the SARS-CoV-2 spike protein in the human host.
Wrobel AG; Benton DJ; Roustan C; Borg A; Hussain S; Martin SR; Rosenthal PB; Skehel JJ; Gamblin SJ
Nat Commun; 2022 Mar; 13(1):1178. PubMed ID: 35246509
[TBL] [Abstract][Full Text] [Related]
39. The Increased Amyloidogenicity of Spike RBD and pH-Dependent Binding to ACE2 May Contribute to the Transmissibility and Pathogenic Properties of SARS-CoV-2 Omicron as Suggested by In Silico Study.
Aksenova AY; Likhachev IV; Grishin SY; Galzitskaya OV
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362302
[TBL] [Abstract][Full Text] [Related]
40. The Omicron (B.1.1.529) variant of SARS-CoV-2 binds to the hACE2 receptor more strongly and escapes the antibody response: Insights from structural and simulation data.
Khan A; Waris H; Rafique M; Suleman M; Mohammad A; Ali SS; Khan T; Waheed Y; Liao C; Wei DQ
Int J Biol Macromol; 2022 Mar; 200():438-448. PubMed ID: 35063482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]